Log In Get Started
Press Releases May 11, 2026 04:05 PM

Immunovant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026, and Provide Business Update on Wednesday, May 20, 2026

Immunovant Announces Date for Q4 and Fiscal Year 2026 Financial Results and Business Update Conference Call

By Marcus Reed
Share
Twitter Reddit Facebook LinkedIn
IMVT

Immunovant, a clinical-stage immunology company focused on autoimmune diseases, announced it will report its financial results for the fourth quarter and fiscal year ended March 31, 2026, via a webcast and conference call on May 20, 2026. The company will also provide a business update during the call.

Immunovant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026, and Provide Business Update on Wednesday, May 20, 2026
IMVT
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Immunovant will release Q4 and full fiscal year 2026 financial results on May 20, 2026.
  • Company will provide a business update to investors during the webcast and conference call.
  • Immunovant focuses on developing anti-FcRn technology to address autoimmune diseases, impacting the biotechnology and pharmaceutical sectors.

DURHAM, N.C., May 11, 2026 (GLOBE NEWSWIRE) -- Immunovant (Nasdaq: IMVT) today announced that it will report its financial results for the fourth quarter and fiscal year ended March 31, 2026, and provide a business update at 8:00 a.m. ET on Wednesday, May 20, 2026.

To access the Roivant (Nasdaq: ROIV) conference call by phone, please register online using this registration link. The presentation and webcast details will also be available under “News & Events” in the Investors section of the Immunovant website at https://www.immunovant.com/investors/news-events/ir-calendar. The archived webcast will be available on Immunovant’s website after the conference call.

About Immunovant 

Immunovant, Inc. is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. As a trailblazer in anti-FcRn technology, the Company is developing innovative, targeted therapies to meet the complex and variable needs of people with autoimmune diseases. For additional information on the Company, please visit immunovant.com. 

Contacts: 

Investors 

Keyur Parekh 

[email protected]  

Media 

Stephanie Lee 

[email protected] 


Risks

  • As a clinical-stage company, Immunovant faces uncertainty regarding future drug approvals and commercial success, impacting biotech investors.
  • Financial results may reflect ongoing R&D expenses and operational costs without current product revenue, which could affect investor sentiment.
  • Market conditions and competitive pressures within the immunology and autoimmune disease treatment sectors could influence company performance.

More from Press Releases

Space Exploration Technologies Corporation to Join the Nasdaq-100 Index® Beginning July 7, 2026 Jun 26, 2026 XMax Announces Up to Approximately US$25 million in AI API-Related Service Contracts and Expansion into GPU-as-a-Service Jun 26, 2026 Cartesian Growth Corporation IV Announces Closing of $275 Million Initial Public Offering Jun 26, 2026 dLocal added to membership of US small-cap Russell 2000® Index Jun 26, 2026 Matinas BioPharma Receives Notice of Non-Compliance with NYSE American Continued Listing Standards and Acceptance of Plan to Regain Compliance Jun 26, 2026